Navigation Links
Agenus to Participate at Two Upcoming Immuno-Oncology Conferences
Date:3/24/2017

LEXINGTON, Mass., March 24, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced participation at the following conferences:

  • The 7th Annual William Blair and Maidstone Life Sciences conference "Cancer Immunotherapy Conference" at the Apella, Event Space Alexandria Center in New York, NY. Agenus will participate in three sessions:
    • March 29 at 9:40 am: Robert B. Stein, M.D., Ph.D., President, R&D will present at a session titled "AutoSynVaxTM and PhosphoSynVaxTM: Next Generation Neoepitope Heat Shock Protein Vaccines" followed by a panel discussion on therapeutic vaccines.
    • March 30 at 10:40 am: Dr. Stein will present at a session titled "Next Generation Immunomodulatory Antibodies: Optimizing Therapeutic Impact."
    • March 30 at 12:00 pm: Jean-Marie Cuillerot, M.D., Chief Medical Officer, will participate in the lunch panel titled "Challenges in Immuno-Oncology Drug Development." 
  • Jefferies Immuno-Oncology Summit at the Boston Harbor Hotel in Boston, MA. Agenus will participate in two sessions:
    • March 30 at 3:00 pm: Jennifer Buell, Ph.D., VP, Global Integrated R&D Operations, will participate in a panel titled "Vaccines – Is There a Future?"
    • March 30 at 3:45 pm: Nick Wilson, Ph.D., Executive Director, Immuno-modulatory Drug Discovery, will participate in a panel titled "Checkpoints - Which Target has the Best Chances of Success?"

About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing a number of combination approaches that leverage a broad repertoire of antibody therapeutics and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is based in Lexington, MA. For more information, please visit www.agenusbio.com; information that may be important to investors will be routinely posted on our website.

Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the upcoming presentations. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Contact:

Agenus Inc.
Michelle Linn, 781-674-4541
michelle.linn@agenusbio.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/agenus-to-participate-at-two-upcoming-immuno-oncology-conferences-300428924.html


'/>"/>
SOURCE Agenus Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. How These Biotech Stocks are Faring? -- Agenus, Tokai Pharma, Eleven Biotherapeutics, and Rexahn Pharma
2. Agenus to Present at the Jefferies 2016 London Healthcare Conference
3. Thad Bench of Benchworks to Participate in 8th Annual Life Science Chief Executive Officer Forum
4. Relmada Therapeutics to Participate in BIO CEO and Investor Conference
5. Exact Sciences to participate in Leerink Partners Global Healthcare Conference
6. Symic Bio to Participate in the 2017 East/West CEO Conference
7. Mannin Research to Participate at ARVO 2016 Meeting
8. Leading Fertility Experts Participate in CCRM Networks Inaugural Scientific Conference
9. Shire to Participate at the Cowen 36th Annual Healthcare Conference
10. Eiger to Participate in Cowen & Company 2016 Health Care Conference
11. Cerapedics to Participate in Canaccord Genuitys Musculoskeletal Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Genedata, ... 20th anniversary, marking the occasion with a strong presence at Bio-IT World Conference ... and further extends an invitation to all attendees to view posters on ...
(Date:5/23/2017)... ... May 23, 2017 , ... Vortex Biosciences , provider of circulating tumor ... circulating tumor cells using Vortex microfluidic technology ” in Nature Precision Oncology on May ... Dino Di Carlo and Dr. Matthew Rettig at the University of California, Los Angeles. ...
(Date:5/23/2017)... Diego, CA (PRWEB) , ... May 23, 2017 , ... ... matrix of polymeric molecules, can cause diverse pathologies ranging from food poisoning and catheter ... impact of biofilms is in the tens of billions of dollars per year, there ...
(Date:5/22/2017)... ... May 22, 2017 , ... Stratevi, a boutique firm that partners with healthcare ... has opened an office in downtown Boston at 745 Atlantic Ave. , “We ... to generate evidence on the value they provide, not just to patients, but also ...
Breaking Biology Technology:
(Date:3/22/2017)... 21, 2017 Optimove , provider ... retailers such as 1-800-Flowers and AdoreMe, today announced ... and Replenishment. Using Optimove,s machine learning algorithms, these ... and replenishment recommendations to their customers based not ... of customer intent drawn from a complex web ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel visited ... to the DERMALOG stand together with the Japanese Prime Minster Shinzo Abe. ... the largest German biometrics company the two government leaders could see the ... well as DERMALOG´s multi-biometrics system.   Continue Reading ... ...
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in Germany ... ... one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial contribution ... ...
Breaking Biology News(10 mins):